Synergistic Effect of Endogenous and Exogenous Aldehydes on Doxorubicin Toxicity in Yeast

BioMed Research International
Jana S MilesHernan Flores-Rozas

Abstract

Anthracyclines are frequently used to treat many cancers including triple negative breast cancer, which is commonly observed in African-American women (AA), and tend to be more aggressive, carry worse prognoses, and are harder to manage because they lack molecular targets. Although effective, anthracyclines use can be limited by serious side effects and eventually the development of drug resistance. In S. cerevisiae, mutants of HOM6 display hypersensitivity to doxorubicin. HOM6 is required for synthesis of threonine and interruption of the pathway leads to accumulation of the threonine intermediate L-aspartate-semialdehyde. This intermediate may synergize with doxorubicin to kill the cell. In fact, deleting HOM3 in the first step, preventing the pathway to reach the HOM6 step, rescues the sensitivity of the hom6 strain to doxorubicin. Using several S. cerevisiae strains (wild type, hom6, hom3, hom3hom6, ydj1, siz1, and msh2), we determined their sensitivity to aldehydes and to their combination with doxorubicin, cisplatin, and etoposide. Combination of formaldehyde and doxorubicin was most effective at reducing cell survival by 31-fold-39-fold (in wild type cells) relative to doxorubicin and formaldehyde alone. This effect was ...Continue Reading

References

Mar 1, 1985·Biochemical Pharmacology·J M SiegfriedT R Tritton
Dec 1, 1994·Current Opinion in Biotechnology·R D Kolodner, E Alani
Jan 1, 1993·Annual Review of Biochemistry·M M Gottesman, I Pastan
Dec 1, 1995·British Journal of Clinical Pharmacology·K T KivistöM Eichelbaum
Mar 1, 1996·General Pharmacology·D NielsenT Skovsgaard
Jul 8, 1997·Proceedings of the National Academy of Sciences of the United States of America·D X TishkoffR D Kolodner
Sep 25, 1999·Clinical Immunology : the Official Journal of the Clinical Immunology Society·R CaricchioP L Cohen
Dec 1, 2001·Clinical Immunology : the Official Journal of the Clinical Immunology Society·I Laux, A Nel
Sep 24, 2005·Current Medicinal Chemistry. Anti-cancer Agents·S M CuttsD R Phillips
Apr 14, 2007·Molecular Cancer Therapeutics·Suzanne M CuttsDon R Phillips
Sep 10, 2009·Biochemical Pharmacology·Michal UgarenkoSuzanne M Cutts
Jan 26, 2010·Critical Reviews in Oncology/hematology·Claudia AndreettaFabio Puglisi
May 17, 2011·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Beshay N M ZordokyAyman O S El-Kadi
Aug 8, 2012·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Abdulaziz M S AlsaadAyman O S El-Kadi
Nov 21, 2012·Pediatrics·Steven E LipshultzUNKNOWN Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium
Nov 18, 2014·Frontiers in Oncology·David A AlagpulinsaRobert Joseph Shmookler Reis
Jul 8, 2015·The Lancet Oncology·Natalie TurnerAngelo Di Leo
Oct 9, 2016·Biopolymers·E F SilvaM S Rocha
Feb 12, 2017·Cardiovascular Drugs and Therapy·John V McGowanDerek M Yellon
May 31, 2017·BioMed Research International·Min XuCheng Lv
Sep 22, 2017·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Ayman ShafeiMahmoud Ellithy
Feb 10, 2018·Biochimica Et Biophysica Acta. General Subjects·Kyung-Hwa JeonYoungjoo Kwon
Feb 24, 2018·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Shizheng LiKun Li

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Methods Mentioned

BETA
PCR
sumoylation

Software Mentioned

GraphPad Prism

Related Concepts

Related Feeds

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
J A Sparano, P H Wiernik
Journal of Nature and Science
Samantha J SojournerHernan Flores-Rozas
Annals of Oncology : Official Journal of the European Society for Medical Oncology
J GehlP Dombernowsky
© 2022 Meta ULC. All rights reserved